Ae­vi shares smashed by a tri­al fail­ure for AD­HD ge­net­ic sub­group

Ae­vi Ge­nom­ic Med­i­cine had all its eggs in one pot. And this morn­ing, that pot got smashed by a land­slide of bad da­ta.

Ae­vi says that its ge­net­ic ap­proach to AD­HD failed to hit the pri­ma­ry end­point in a study dubbed SAGA. AE­VI-001 failed to sig­nif­i­cant­ly help AD­HD pa­tients with mu­ta­tions that throw a mon­key wrench in the mGluR net­work, dis­rupt­ing glu­ta­mate.

The com­pa­ny’s stock $GN­MX was evis­cer­at­ed, plung­ing 68% on the news.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER